Loading stock data…
SRPT
$19.40-0.56 (-2.78%)
Market ClosedLast close May 11
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sarepta Therapeutics, Inc. in the Healthcare sector is trading at $19.40. The stock is currently 56% below its 52-week high of $44.14, remaining 2.5% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why SRPT maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.40
Potential Upside
5%
Whystock Fair Value$20.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Hold
Mean target$22.00+13.4%
Range$5.00 – $38.00
Fundamentals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.08%
Volume
Today's trading volume
3.07M
Recent News
A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress
Sarepta Therapeutics (SRPT) just posted first quarter 2026 results that shifted the story for the stock, with a move back to profitability, an earnings beat versus expectations, and reaffirmed full year revenue guidance. See our latest analysis for Sarepta Therapeutics. Despite the Q1 earnings beat and reaffirmed guidance, the stock has been under pressure, with a 1-month share price return decline of 9.88% and a 1-year total shareholder return loss of 43.04%, indicating fading longer term...
Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says
Sarepta Therapeutics' (SRPT) commercial portfolio alone should support a higher valuation, while the
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.
Sarepta tumbles as its gene therapy sales decline further
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.